A group of seven Qiming-affiliated entities filed Amendment No. 2 to Schedule 13G with the SEC on November 3, 2026, disclosing their beneficial ownership positions in Connect Biopharma Holdings Ltd, a clinical-stage biopharmaceutical company headquartered in San Diego, California, as of a September 30, 2026 event date.

Key Highlights

  • Seven reporting persons: Qiming Corporate GP V, Ltd.; Qiming Managing Directors Fund V, L.P.; Qiming GP V, L.P.; Qiming Venture Partners V, L.P.; Qiming GP VII, LLC; Qiming Venture Partners VII, L.P.; and Qiming VII Strategic Investors Fund, L.P. each filed separate ownership disclosures.
  • Largest reported stake: Qiming Corporate GP V, Ltd. reported aggregate beneficial ownership of 1,821,426 ordinary shares, representing 2.9% of the class, with sole voting and dispositive power over all shares.
  • Qiming Venture Partners V, L.P. and Qiming GP V, L.P.: Each reported beneficial ownership of 1,766,600 ordinary shares, representing 2.8% of the class.
  • Qiming GP VII, LLC: Reported beneficial ownership of 935,064 ordinary shares, representing 1.5% of the class, held through two underlying funds.
  • Shares outstanding basis: All percentages were calculated using 62,974,309 ordinary shares issued and outstanding as of July 31, 2026, as reported in the issuer's filing with the SEC on August 12, 2026.
  • Security described: Ordinary shares with a par value of US$0.000174 per share, CUSIP G23549101.

Qiming Entities Disclose Ownership Positions in Connect Biopharma Ordinary Shares

According to the filing, all seven reporting persons are organized in the Cayman Islands and share a registered address at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman. The event triggering this amendment occurred on September 30, 2026. Connect Biopharma Holdings Ltd, the issuer, is a biopharmaceutical company with principal executive offices located at 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130, and its ordinary shares carry a par value of US$0.000174 per share.

The filing describes an interconnected ownership structure among the reporting entities. Qiming Corporate GP V, Ltd. serves as the general partner of both Qiming Managing Directors Fund V, L.P. ("QMD V") and Qiming GP V, L.P. ("QGP V"), according to the filing. QGP V in turn acts as the general partner of Qiming Venture Partners V, L.P. ("QVP V"). The filing states that QMD V holds 54,826 ordinary shares and QVP V holds 1,766,600 ordinary shares, with Qiming Corporate GP V, Ltd. reporting combined beneficial ownership of 1,821,426 shares at 2.9% of the class.

Separately, the filing discloses that Qiming GP VII, LLC is the general partner of Qiming Venture Partners VII, L.P. and Qiming VII Strategic Investors Fund, L.P., which hold 926,527 ordinary shares and 8,537 ordinary shares, respectively. Each reporting person disclosed zero shared voting power and zero shared dispositive power, with all voting and dispositive authority held solely by the respective reporting person. The smallest position disclosed belongs to Qiming VII Strategic Investors Fund, L.P., with 8,537 ordinary shares, representing 0.0% of the class as reported in the filing.

What Was Disclosed

Seven Cayman Islands-based Qiming investment entities filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership of ordinary shares in Connect Biopharma Holdings Ltd as of September 30, 2026, with individual positions ranging from 8,537 to 1,821,426 shares and ownership percentages from 0.0% to 2.9%.